Answers are grounded in this paper and cite their sources.
Current clinical tools for epilepsy monitoring have well-defined limitations. Seizure diaries undercount non-convulsive events, cognitive screening lacks process-level resolution, and plasma drug monitoring reflects pharmacokinetic exposure rather than neural effects. Eye tracking provides a complementary approach by capturing oculomotor behavior that is continuously quantifiable, does not rely on patient self-report, and depends on cortical and subcortical circuits affected by epileptogenic pathology and antiseizure medications. This review examines eye tracking as a translational biomarker approach across four domains: cognitive phenotyping, pharmacodynamic monitoring, seizure semiology, and presurgical functional mapping, and grades the evidence maturity of each domain from discovery to clinical utility. Impaired antisaccade and other voluntary saccade performance is the most frequently replicated finding, reported in several small cohorts and in one recent single-center cohort of 442 adults. It is consistent with executive dysfunction that standard screening may miss, but it has not been validated externally, and current data cannot fully separate disease effects from medication effects. Saccade dynamics are an established pharmacodynamic marker in clinical pharmacology, but epilepsy-specific evidence is limited to one study comparing treated patients with controls, which did not measure plasma drug levels. In contrast, semiology quantification and presurgical applications remain at an early stage of development. The main barriers to clinical translation are methodological, with additional hardware constraints for ambulatory use. Existing studies are small, cross-sectional, and heterogeneous, with limited use of concurrent EEG during cognitive paradigms and inconsistent reporting of acquisition and preprocessing methods. Because similar oculomotor abnormalities occur in other neurological and psychiatric disorders, these measures are better viewed as transdiagnostic markers of network dysfunction than as epilepsy-specific biomarkers. Addressing these gaps requires standardized protocols, validated analysis pipelines, and longitudinal, multi-site study designs. Eye tracking is unlikely to replace existing clinical tools, but may extend their application by providing objective, process-level measures of neural function.
No takes yet. Share an insight, caveat, or question.
Kalinina et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: